A Case Report on PRES and HELLP Syndrome in 08 Months Amoneherric Women

Priyancy Patel *

Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Vadodara, Gujarat, India.

Khushi Thakor

Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Vadodara, Gujarat, India.

Monil Dabgar

Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Vadodara, Gujarat, India.

Snigdha Das Mandal

Department of Pharmacy Practice, Pharmacology, Parul Institute of Pharmacy & Research, Parul University, Vadodara, Gujarat, India.

*Author to whom correspondence should be addressed.


Abstract

Posterior Reversible Encephalopathy Syndrome (PRES), in 1996 was originally described by Hinchey. It is also so-called as reversible posterior leukoencephalopathy syndrome, an illness in which a person present’s with acutely altered mentation, visual impairment, drowsiness or sometimes stupor, seizures (focal or general tonic-clonic), and sudden or constant, non-localized headaches, and nausea and vomiting. If recognized promptly and treated, the clinical syndrome generally resolves within a week, and the variations seen in magnetic resonance imaging (MRI) resolve over days to weeks. The syndrome of hemolysis, elevated liver enzymes, and low platelets, is referred to as HELLP syndrome, has historically been classified as a complication or progression of severe preeclampsia. An ischemic-reperfusion injury initiates the liver damage in HELLP syndrome. The clinical presentation may vary from patient to patient with HELLP syndrome, and may present with colicky mid-epigastric and/or right upper quadrant pain associated with fatigue, nausea and vomiting. An appropriate physical examination must be conducted if any of the above complications are suspected.

Keywords: Posterior reversible encephalopathy syndrome (PRES), hemolysis, elevated liver enzymes and low platelets (HELLP)


How to Cite

Patel, P., Thakor, K., Dabgar, M., & Mandal, S. D. (2022). A Case Report on PRES and HELLP Syndrome in 08 Months Amoneherric Women. Asian Journal of Case Reports in Medicine and Health, 5(1), 220–225. Retrieved from https://journalajcrmh.com/index.php/AJCRMH/article/view/144

Downloads

Download data is not yet available.

References

Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500.

DOI: 10.1056/NEJM199602223 340803

McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007;189:904–12.

Fischer M,Schmutzhard E, Posterior reversible encephalopathy syndrome. Journal of Neurology; 2017.

[PubMed PMID: 28054130]

Pereira PR, Pinho J, Rodrigues M, Rocha J, Sousa F, Amorim J, Ribeiro M, Rocha J, Ferreira C. Clinical, imagiological and etiological spectrum of posterior reversible encephalopathy syndrome. Arq Neuropsiquiatr. 2015;73:36-40.

Zhang L, Wang Y, Shi L, Cao J, Li Z, Wáng YX. Late postpartum eclampsia complicated with posterior reversible encephalopathy syndrome: A case report and a literature review. Quant Imaging Med Surg. 2015;5:909-16.

Pavlidou E, Pavlou E, Anastasiou A, Pana Z, Tsotoulidou V, Kinali M, Hatzipantelis E. Posterior reversible encephalopathy syndrome after intrathecal methotrexate infusion: a case report and literature update. Quant imaging Med Surg. 2016;6:605-11.

Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, et al. Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol. 1992; 159:379–83.

DOI: 10.2214/ajr.159.2.1632361

Schwartz RB, Bravo SM, Klufas RA, Hsu L, Barnes PD, Robson CD, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol. 1995; 165:627–31.

DOI: 10.2214/ajr.165.3.7645483

Bartynski WS, Grabb BC, Zeigler Z, Lin L, Andrews DF. Watershed imaging features and clinical vascular injury in cyclosporin A neurotoxicity. Comput Assist Tomogr. 1997;21:872–80.

DOI:10.1097/00004728-199711000- 00005

Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol. 2001;22:1901–14.

Roth C, Ferbert A. The posterior reversible encephalopathy syndrome: What’s certain, what’s new? Pract Neurol. 2011;11:136–44.

Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500.

Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010 ;85:427–32.

Van Lieshout LCEW,Koek GH, Spaanderman MA,van Runnard Heimel PJPlacenta derived factors involved in the pathogenesis of the liver in the syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP): A review. Pregnancy hypertension; 2019.

[PubMed PMID: 31494464]

Sadaf N, Haq G, Shukar-ud-Din S. Maternal and foetal outcome in HELLP syndrome at tertiary care hospital. JPMA. The Journal of the Pakistan Medical Association; 2013.

[PubMed PMID: 24397093]

Stojanovska V, Zenclussen AC. Innate and Adaptive Immune Responses in HELLP Syndrome. Front Immunol. 2020; 11:667.

[PMC free article] [PubMed]

Haram K,Svendsen E,Abildgaard U, The HELLP syndrome: clinical issues and management. A Review. BMC pregnancy and childbirth; 2009.

[PubMed PMID: 19245695]

Böhmer AB, Wappler F, Zwissler B. Preoperative risk assessment—from routine tests to individualized investigation. Deutsches Ärzteblatt International. 2014 Jun;111(25):437.